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Abstract
Background and Objective: The prognosis varied among the patients with the same stage, therefore there was a need for
new prognostic and predictive factors. The aim of this study was to evaluate the relationship of apoptosis-related biological
markers such as p53, bcl-2, bax, and c-myc, and clinicopathological features and their prognostic value.
Methods: From 1996 to 2007, 4426 patients had undergone curative D2 gastrectomy for gastric cancer at Fudan University
Shanghai Cancer Center. Among 501 patients, the expression levels of p53, bcl-2, bax, and c-myc were examined by
immunohistochemistry. The prognostic value of biological markers and the correlation between biological markers and
other clinicopathological factors were investigated.
Results: There were 339 males and 162 females with a mean age of 57. The percentages of positive expression of p53, bcl-2,
bax, and c-myc were 65%, 22%, 43%, and 58%, respectively. There was a strong correlation between p53, bax, and c-myc
expression (P=0.00). There was significant association between bcl-2, and bax expression (P,0.05). p53 expression
correlated with histological grade (P=0.01); bcl-2 expression with pathological stage (P=0.00); bax expression with male
(P=0.02), histological grade (P=0.01), Borrmann type (P=0.01), tumor location (P=0.00), lymph node metastasis (P=0.03),
and pathological stage (P=0.03); c-myc expression with Borrmann type (P=0.00). bcl-2 expression was related with good
survival in univariate analysis (P=0.01). Multivariate analysis showed that bcl-2 expression and pathological stage were
defined as independent prognostic factors. There were significant differences of overall 5-year survival rates according to
bcl-2 expression or not in stage IIB (P=0.03).
Conclusion: The expression of bcl-2 was an independent prognostic factor for patients with gastric cancer; it might be a
candidate for the gastric cancer staging system.
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Introduction
Although the incidence of gastric cancer has been substantially
declining for several decades, it was still the fourth most common
cancer and the second most frequent cause of cancer death [1,2].
It was very important to predict precisely the risk of poor prognosis
in order to maximize the therapeutic effect and to minimize the
adverse effects in the treatment of cancer patients. Among the
prognostic factors now available for gastric cancer, the most
precise and important prognostic factor was the UICC TNM
stage. As a result of the variability of prognosis within the same
stage of gastric cancer, it was impossible to precisely predict the
prognosis through the conventional staging procedures. Therefore,
it was essential to search for the other specific factors to identify
subgroups of patients with more aggressive course of the disease.
Recently, some studies have shown that other pathological factors,
such as the number of positive lymph nodes, the presence of
extracapsular lymph node involvement, and tumor size had
additional prognostic value [3–5]. Given that some biological
markers, such as oncogenes, tumor-suppressor genes, cell-cycle
regulators, and DNA repair genes, were related to tumor genesis,
growth, invasion and metastasis, many scientists were dedicated to
searching for the new prognostic factors with these molecular
markers. Despite of the fact that a few of studies have evaluated
the prognostic significance of the markers, such as p53, bcl-2, bax,
and c-myc in gastric cancer, the results were controversial [6–11].
Moreover, these previous studies were conducted to research the
additional prognostic value of the markers to the 6th UICC TNM
stage, it was urgent to elucidate the relationship between these
makers and the 7th UICC TNM stage. At last, there were no
studies evaluating the expression of these molecular prognostic
significance in gastric cancer patients in China. Therefore, we
evaluated the expression of biological markers such as p53, bcl-2,
bax, and c-myc in this study.
p53 proteins were the products of tumor-suppressor genes,
which acted by modulating cell proliferation via control of the G1
arrest checkpoint of the cell cycle [12,13]. bcl-2 and bax belonged
to the bcl-2 family, and the latter was one of the most relevant
classes of apoptosis regulatory molecules. The bcl-2 family were
classified into two subfamilies: anti-apoptosis proteins (bcl-2, bcl-
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(bax, bak, bcl-Xs, bad, bid, and hrk) [14]. It has been shown that
the bax to bcl-2 could affect the relative sensitivity or resistance of
cells to apoptotic simuli [15]. c-myc protein was a type of
transcription factor. A previous study showed the c-myc expression
was linked with cell proliferation [16].
In this study, we evaluated the expression of biological markers
such as p53, bcl-2, bax, and c-myc, correlated their expression to
clinicopathological characteristics and evaluated their prognostic
value.
Materials and Methods
Patients
During January 1996 and December 2007, 4426 patients with
histologically confirmed primary gastric adenocarcinoma under-
went curative D2 gastrectomy at the Department of Gastric
Cancer and Soft Tissue Sarcoma in Fudan University Shanghai
Cancer Center. Out of these patients, 501 cases were selected, as
their specimens were stained immunohistochemically after oper-
ation with routine histological examination. Data were retrieved
from patients’ operative and pathological reports, and follow-up
data were obtained by phone, letter, and the outpatient clinical
database. This study comprised 339 men and 162 women aged
from 22 to 82 years old, mean age was 57 years. Staging was
performed according to the UICC TNM Staging Classification for
Carcinoma of the Stomach (Seventh Edition, 2010). A follow-up of
all patients was carried out according to our standard protocol
(every three months for at least 2 years, every six months for the
next 3 years, and after 5 years every 12 months for life). The
check-up items included physical examination, tumor-marker
examination, ultrasound, chest radiography, computed tomo-
graphic scan, and endoscopic examination. The median follow-up
time was 44.6 months at the time of analysis. The written informed
consent had been obtained from all the patients, and this study was
approved by the Ethical Committee of Shanghai Cancer Center of
Fudan University. The study was retrospective.
Immunohistochemical staining
p53, bcl-2, bax, and c-myc weredetected by immunohistochemical
method. All primary antibodies and mouse monoclonal antibodies
were purchased from Dako (Hamburg. Germany). Immunohisto-
chemical staining was performed by the enhance labeled polymer
system (ELPS) method, with 10% formalin-fixed, paraffin-embedded
materials. Serial 5 mm paraffin sections were deparaffinised with
xylene and hydrated with ehanol/deionized water. Sections were
then incubated with methanol/0.3% H2O2 for 10 min and blocked
with non-specific staining blocking reagent. After overnight incuba-
tion at 4uC with anti-p53, bcl-2, bax, and c-myc antibody (diluted
1:100, 1:100, 1:100, 1:100, respectively), sections were treated
according to standard immunoperoxidase methods using a strepta-
vidin biotin peroxidise complex kit (LSAB+Kit/HRP; Dako). The
peroxidise reaction was then developed with diaminobenzidine
(Dako). Negative control sections were subjected to the same
procedure except that the first antibody was replaced by PBS. No
positive staining was observed in the controls. The position of staining
was predominantly in cell cytoplasm for bax and c-myc, cytoplasm
and cytomembrane for bcl-2, nucleus for p53.
Immunohistochemical staining scoring
All the slices were evaluated by two pathologists without
knowledge of clinical outcome. The percentage of immunoreactive
cells and staining intensities were evaluated in each sample. The
percentage of immunoreactive cells was graded on a scale of 0 to 4:
no staining is scored as 0, 1–10% of cells stained scored as 1, 11–
50% as 2, 51–80% as 3, and 81–100% as 4. The staining
Figure 1. Positive expression of apoptosis-related biological markers immunohistochemistry in gastric cancer tissue. A) Positive
expression of p53. B) Positive expression of bcl-2. C) Positive expression of bax. D) Positive expression of c-myc. (Original magnification: all 6100).
doi:10.1371/journal.pone.0029670.g001
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weak, 2 as moderated, and 3 as strong, respectively. The raw data
were converted to the immunohistochemical score (IHS) by
multiplying the quantity and intensity scores. An IHS score of 9–
12 was considered as strong immunoreactivity (+++), 5–8 as
moderate (++), 1–4 as weak (+), and 0 as negative (2). On the final
analysis, the cases had a score of less than 1 were considered as
negative, and $1 was regarded as positive.
Statistical analysis
The association between clinicopathological factors and biolog-
ical markers was evaluated by Chi-square test. Five-year survival
rate was calculated by Kaplan-Meier method, and differences
between survival curves were examined with log-rank test. All the
significant variables observed in univariate analysis were included
into the multivariate survival analysis using Cox proportional
hazards model. The accepted level of significance was P,0.05.
Statistical analyses and graphics were performed using the SPSS
13.0 statistical package (SPSS, Inc., Chicago, IL).
Results
Clinicopathological characteristics
There were 339 males and 162 females (2.09:1) with a mean age
of 57 years. There was 57 (11.4%) early gastric cancers and 444
(88.6%) advanced gastric cancers. According to histological type,
well-differentiated tumors were observed in 9 (1.8%) patients,
moderately-differentiated in 164 (32.7%) patients, and poorly-
differentiated tumors in remaining 328 (65.5%) patients. Accord-
ing to Borrmann type, 57 (10.4%) were type 0, 36 (7.2%) type I, 15
(3.0%) type II, 371 (74.0%) type III, 22 (4.4%) type IV. Of 501
Table 1. Positive results of correlations among
immunohistochemical markers.
Immunohistochemical markers
Correlation
coefficients (r) P value
p53 Bax 0.097 0.029
p53 c-myc 0.171 0.000
bcl-2 Bax 0.139 0.002
Bax c-myc 0.132 0.003
doi:10.1371/journal.pone.0029670.t001
Table 2. Positive results of correlations between immunohistochemical markers and clinicopathological parameters.
Variable p53+ Bcl-2+ bax+ c-myc+
n% P % P % P % P
Sex 0.156 0.980 0.016 0.549
Female 162 60.5 22.2 35.2 56.2
Male 339 66.9 22.1 46.6 58.9
Age (y) 0.239 0.676 0.733 0.720
,60 284 62.7 21.5 42.3 57.4
$60 217 67.7 23.0 43.8 58.9
Histological type 0.000 0.178 0.006 0.190
well-differentiated 9 88.8 0.00 44.4 66.6
moderately-differentiated 164 72.6 25.0 53.0 63.4
poorly-differentiated 328 60.3 21.3 37.8 55.2
Tumor site 0.421 0.623 0.000 0.649
Upper third 159 66.7 23.8 55.9 59.7
Middle Third 72 59.7 18.1 27.8 62.5
Low third 244 63.9 22.9 39.3 55.3
Two-thirds or more 26 76.9 15.4 38.5 61.5
Borrmann type 0.454 0.332 0.002 0.002
0 57 56.1 14.0 19.3 33.3
I 36 66.7 25.0 41.7 55.5
II 15 60.0 33.3 53.3 60.0
III 371 65.5 23.2 46.9 62.2
IV 22 77.3 13.6 31.8 54.5
Lymph nodes status 0.152 0.248 0.025 0.214
Yes 356 62.9 20.7 46.1 59.8
No 145 69.6 25.5 35.2 53.8
Pathological stage 0.561 0.000 0.026 0.243
I 87 60.9 18.4 29.8 51.7
II 143 67.8 34.3 46.1 55.9
III 271 64.6 16.9 45.4 61.3
doi:10.1371/journal.pone.0029670.t002
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(14.4%) had tumors in the middle third, 244 (48.7%) had tumors
in the lower third of the stomach, and 26 (5.2%) had tumors
occupied two-thirds or more of stomach. Lymph node metastasis
was observed in 356 patients, the metastasis rate was 71.1%. The
distribution of pathological stage was as follows: 35 (7.0%) patients
belonged to stage IA, 52 (10.4%) IB, 60 (12.0%) IIA, 83 (16.5%)
IIB, 88 (17.6%) IIIA, 83 (16.5%) IIIB, and 100 (20.0%) IIIC.
p53 expression
p53 expression was positive in 64.9% of all gastric cancer
tissues. p53 staining was observed in the nucleus of carcinoma cells
(Figure 1). p53 expression was associated with bax and c-myc
(Table 1). Well-differentiated histology correlated with p53
expression. There was no correlation with gender, age, Borrmann
type, tumor location, lymph node metastasis, and pathological
stage (Table 2).
bcl-2 expression
bcl-2 expression waspositivein 22.2%of all gastriccancer tissues.
bcl-2 staining was observed in the cytoplasm and cytomembrane of
carcinoma cells (Figure 1). bcl-2 expression was associated with bax
(Table 1). There was correlation with pathological stage, but no
correlation with gender, age, histological type, Borrmann type,
tumor location, lymph node metastasis, and (Table 2).
bax expression
bax expression was positive in 42.9% of all gastric cancer tissues.
bax staining was observed in the cytoplasm of carcinoma cells
(Figure 1). bax expression was associated with p53, bcl-2 and
c-myc (Table 1). Female gender, moderately-differentiated,
Borrmann II, upper third location, and lymph node metastasis
correlated with bax expression. As the pathological stage
increased, the expression of bax became more frequent. There
was no correlation with age (Table 2).
c-myc expression
c-myc expression was positive in 58.1% of all gastric cancer
tissues. c-myc staining was observed in the cytoplasm of carcinoma
cells (Figure 1). c-myc expression was associated with p53, and bax
(Table 1). Borrmann III correlated with c-myc expression. There
was no correlation with gender, age, histological type, tumor
location, lymph node metastasis, and pathological stage (Table 2).
Additionally, raw data on clinicopathological features and
immunoreactivity evaluations for 501 cases of gastric cancer was
showed as a supplementary table in an Excel format (Table S1).
Univariate analysis
The over-allfive-yearsurvival rate was 53.7% forall 501patients.
Five-year survival rate was 64.9% and 50.5% in bcl-2 positive and
bcl-2 negative patients respectively, and this difference was
statistically significant (Fig. 2). Except for bcl-2 expression, the
significant prognostic factors included: tumor site, Borrmann type,
status of lymph nodes, and pathological stage. Table 3 showed
findings at univariate analysis for prognostic factors.
Multivariate analysis
Multivariate survival analysis, including all significant prognos-
tic factors mentioned in univariate analysis, was performed to
determine the independent prognostic factors for gastric cancer.
Figure 2. Kaplan-Meier survival curves according to the expression of bcl-2. There were significant differences between bcl-2+ and bcl-22
(P=0.005).
doi:10.1371/journal.pone.0029670.g002
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showed that bcl-2 expression and pathological stage were
independent prognostic factors (Table 4).
Comparison of survival according to biological markers
at same stage
According to 7th UICC TNM Staging System, gastric cancer
was divided into 7 stages: stage IA, stage IB, stage IIA, IIB, IIIA,
IIIB, IIIC. Basing on the bcl-2 expression, each stage was divided
into bcl-2 positive and bcl-2 negative group. There were significant
differences of over-all 5-year survival between bcl-2 positive and
bcl-2 negative group according to stage IIB (P=0.003). Addition-
ally, we found that there were significant differences of over-all 5-
year survival between bcl-2 positive and bcl-2 negative group
according to Borrmann III (P=0.002); no significant differences
according to stage II and stage III (Figure 3).
Discussion
The identification of prognostic factors in gastric cancer was
essential for predicting patients’ survival and determining optimal
therapeutic strategies. Manystudies have indicated that the depth of
invasion and lymph node metastasis were the most important
prognostic factors in gastric cancer [17,18]. As a result of the
variability of prognosis within same pathological stage of gastric
cancer, there have been a lot of researches for specific biological
markers to identify patients with poorer prognosis [19–21].
Meanwhile, the expression of p53, bcl-2, bax, and c-myc were
known for being related with tumorogenesis. Therefore, the aim of
this study was to investigate whether these biological markers canbe
used as additional prognostic factors to traditional TNM stage in
gastric cancer. In this study, the expression of these proteins was
investigated in 501 cases of resected primary human gastric cancers.
Table 3. Univariate analysis of all patients by Kaplan-Meier method.
Variable n 5-Year survival rate (%) Log rank x
2 value P value
Sex 0.374 0.541
Female 162 56.8
Male 339 52.2
Age (y) 0.484 0.487
,60 284 56.0
$60 217 50.7
Tumor site 31.896 0.000
Upper third 159 42.8
Middle third 72 44.4
Lower third 244 66.0
Two-thirds or more 26 30.8
Borrmann type 43.615 0.000
0 57 87.7
I 36 44.4
II 15 60.0
III 371 50.9
IV 22 22.7
Lymph nodes metastasis 63.969 0.000
Yes 356 42.1
No 145 82.1
Pathological stage 106.030 0.000
I 87 93.1
II 143 65.0
III 271 35.1
Bcl-2 7.712 0.005
+ 111 64.9
2 390 50.5
doi:10.1371/journal.pone.0029670.t003
Table 4. Multivariate analysis of patients by Cox model.
Variable x
2 P vale RR 95% CI
Sex 0.123 0.726 1.053 0.788–1.409
Age 2.257 0.133 0.816 0.625–1.064
Borrmann type 0.128 0.721 1.035 0.858–1.247
Lymph node metastasis 1.227 0.268 0.739 0.433–1.262
Tumor site 3.500 0.061 0.880 0.770–1.006
Pathological stage 45.611 0.000 1.517 1.344–1.712
Bcl-2 4.935 0.026 1.491 1.048–2.121
doi:10.1371/journal.pone.0029670.t004
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and c-myc were 64.9%, 22.2%, 42.9%, 58.1%, respectively, and
these results were consistent with the expression rates of other
studies reported as 17–84.1%, 12.7–67%, 42.4–58.0%, 23.5–
72.9%, respectively [9,12,22–26]. p53 played an important role in
apoptosis. It altered most frequently in human cancer. Wild-type
p53 protein induced growth arrest at the G1/S phase of cell cycle
in response to DNA damage, thus preventing the proliferation of
cells. Muted-type p53 lost the function, and allowed cells with
damaged DNA to proliferate. In this study, a reverse correlation
between p53 and histological type was found, which demonstrated
that deregulation of p53 might result in uncontrolled proliferation
in gastric cancer. It was consistent with a previous study [22]. It
was controversy as for the prognostic value of p53, some studies
have reported that p53 was associated with poor prognosis
[27,28], while others reported that p53 has no influential on
prognosis [29,30]. Our research showed that p53 was not related
to the prognosis of gastric cancer. bax acted as an accelerator of
apoptosis on cell life. A previous study proposed that the ratio of
bax to bcl-2 played a critical role in regulating the propensity for
apoptosis [31]. In the present study, the expression of bax was
associated with that of bcl-2, and bax overexpression correlated
significantly with some clinicopathological features such as gender,
histological type, Borrmann type, tumor location, and lymph node
metastasis. We found that the patients with positive expression of
bax were prone to present lymph node metastasis, and bax was not
an independent prognostic factor. This result was different from a
previous research. Anagnostopoulos et al. [24] reported that
negative bax expression in gastric was associated with lymph node
metastasis and poor clinical prognosis. The reasons for the
conflicting results were not clear. It was possible that the gene
differences between western people and eastern people contribut-
ed to this. The proto-oncogene c-myc was a master regulator of
cell proliferation and transformation through both transcriptional
and nontranscriptional means, and was frequently deregulated in
human malignancies. Ninomiya et al. [26] reported that excess
reactivity to c-myc product occurred more frequently in invasive
cancers than in localized cancers, and c-myc production
Figure 3. Comparison of survival according to Borrmann III and tumor stage. A) There were significant differences between bcl-2+ group
and bcl-22 group according to Borrmann III (P=0.002). B) There were no significant differences according to stage II. C) There were no significant
differences according to stage III.
doi:10.1371/journal.pone.0029670.g003
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dissemination, and patients with c-myc positive expression had
poorer prognosis than those with c-myc negative expression. In
present study, we did not find any relationship between c-myc
expression and invasive behaviour and prognosis other than
Borrmann type. We found that c-myc expression was more
associated with Borrmann III.
The bcl-2 gene was firstly described as an oncogene in follicular
lymphoma. It was well known to inhibit apoptosis [32], but some
studies have reported that overexpression of bcl-2 suppressed
cellular proliferation and was associated with less aggressive
biological behaviour [33,34]. bcl-2 has been reported in a variety
of human epithelial malignant tumors including gastric carcinoma.
However, the exact role and clinical significance of bcl-2 remained
to be elucidated. Previous studies have shown that the expression
of bcl-2 was associated with better prognosis in non-small-cell lung
cancer and gastric cancer [35,36]. Pietenpol et al. [37] reported
that overexpression of bcl-2 inhibited the growth of several solid
tumor cell lines. Saegusa et al. [33] demonstrated that the majority
of bcl-2+ cancer cells was in a nonproliferative state, and the
average expression of Ki-67 labeling index and apoptotic labelling
index in bcl-2+ foci were significantly lower than that in bcl-2- foci.
Aizawa et al. [36] showed that the expression of bcl-2 in advanced
gastric cancer was associated with a lower apoptotic index and a
better prognosis. All these studies suggested that bcl-2 not only
inhibited apoptosis, but also suppressed cellular proliferative
activity. In present study, we characterized for the first time the
expression of bcl-2 proteins in Chinese gastric cancer patients. Our
data showed that bcl-2 was significantly correlated with better
survival.
The identification of prognostic factors in gastric cancer was
essential for predicting patients’ survival and determining optimal
therapeutic strategies. It was well known that the depth of invasion
and the presence or absence of lymph node metastasis were the
most important prognostic factors in gastric cancer. However, it
was impossible to precisely predict the prognosis through the
conventional staging procedures as a result of the variability of
prognosis within the same stage of gastric cancer. Liu et al. [5]
found that there were significant differences between the larger-
size tumor group and the small-size tumor group according to
stage IIIb and IV. Therefore, it was essential to search for the
other specific factors to identify subgroups of patients with more
aggressive course of the disease especially in the 7th editions of the
UICC TNM Staging System. According to the 7th UICC TNM
classification, each stage of gastric cancer was further divided into
bcl-2 positive and bcl-2 negative group. Our data showed that the
expression of bcl-2 greatly influenced prognosis in stage IIB. The
results indicated that the expression of bcl-2 could provide
additional prognostic information in the patients with gastric
cancer.
Some limitations of this study should be acknowledged. Firstly,
the status of Helicobacter pylori was not described. As a crucial
carcinogen of gastric cancer, Helicobacter pylori could be linked
to some other parameters such as bcl-2. Secondly, the relationship
between tumor recurrence and bcl-2 was not investigated.
In conclusion, the expression of bcl-2 can serve as one useful
indicator for predicting the prognosis of patients with gastric
cancer. Therefore, it might be a candidate for the staging system in
addition to conventional factors.
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